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Abstract 
Purpose: To investigate the antibody effect of immunace on the adjuvanticity of 1,2-dioleoyl-3-
trimethylammoniumpropane (DOTAP)- based liposomes. 
Method: The vesicles of the liposome-based ND vaccine were prepared by lipid film hydration method 
and physically characterized for shape, particle size and zeta potential. Forty experimental birds were 
divided into an unvaccinated group, a liposomal Newcastle disease (ND) vaccine group, combined 
liposomal ND vaccine and immunace group, and a live La Sota® vaccine group. The liposomal ND 
vaccine, liposomal ND vaccine and immunace and a live La Sota® vaccine groups were vaccinated 
orally at 3 and 6 weeks of age. Haemagglutination inhibition test was carried out after primary and 
booster doses.  
Results: The log2 mean antibody titre induced by the liposomal ND vaccine after secondary 
immunization of the birds was 9.60 ± 0.95 while that of the combined liposomal ND vaccine and 
immunace group was 7.00 ±1.71, and that of the live La Sota vaccine® was 6.00 ±0.63. There was no 
detectable antibody in the unvaccinated group throughout the experiment. At p < 0.05, the liposomal ND 
vaccine group, after secondary immunization, produced antibodies which were significantly higher than 
those of the combined immunace-liposomal ND vaccine group.  
Conclusion: There was a boost in the immune response of the birds immunized with liposomal ND 
vaccine and immunace after primary immunization only.  
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Newcastle disease (ND) is a contagious and fatal 
viral disease affecting both wild and domestic 
avian species [1,2]. The impact of ND is most 
notable in controlled poultry due to its high 
susceptibility [2]. ND has been reported to 
represent a stronger drain on the world economy 
than any other animal viral disease. It is probably 
the most serious global disease of poultry. 
Vaccination programmes are now designed to 
hyperimmunize chickens effectively to protect 
them from field/virulent strains of the ND virus, 
and for the vaccines to be effective it is important 
that they are delivered properly and effectively. 
  
Lately, the advances in dosage forms have 
resulted in the development and improvement of 
drug delivery systems. From earliest times, man 
has devised different approaches and 
mechanisms to introduce therapeutic agents into 
the body. Currently, the approaches have 
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evolved into cutting-edge nanotechnologies that 
have improved drug release profile, absorption, 
targeting and overall bioavailability. Many 
medications such as peptides and proteins, 
antibody, vaccines, gene based drugs which are 
subject to enzymic degradation by proteinases, 
peptidases, nucleases etc have been protected 
by encapsulating in carriers like liposomes, 
niosomes, virosomes, dendrons, nanoemulsions, 
nanospheres and polymer based nanoparticles 
[3,4]. They are effective and they target the drug 
to specific sites for effective and safe delivery. 
 
Vaccines are immunological products that are 
capable of inducing the production of antibodies. 
Vaccines based on recombinantly made subunit 
and synthetic- peptide antigens are usually non-
immunogenic, and the need for adjuvanticity is 
essential. They are however not ideal because 
they induce only humoral immunity but not cell-
mediated and cannot be lyophilized. Recently, 
there has appeared a vaccine adjuvant 
candidate, liposome, with a liposome-based 
vaccine (against hepatitis A) being licensed for 
use in humans [4,5].Vaccines based on 
novasomes (non-phospholipid liposomes formed 
from single-chain amphiphiles, with or without 
other lipids) have been licensed for the 
immunization of fowl against Newcastle disease 
virus and avian rheovirus [5,6]. Other liposomal 
or novasome-based vaccines against bacterial 
and viral infections are under development. 
Liposomes are biodegradable and non-toxic and 
can elicit both humoral and cell-mediated 
immunity and are easy to prepare [6,7].They are 
highly versatile in their structural characteristics 
which can be modified/manipulated to improve 
their adjuvanticity [6,7,9], e.g. surface charge, 
lamellarity, fluidity, pH sensivity, vesicle size, 
antigen association, etc. There are detailed 
information available on the fate of liposomes 
after uptake by cells and the subsequent 
induction of cytotoxic T-lymphocyte responses. 
Liposomes are immunological adjuvants that are 
capable of augmenting immune responses to 
entrapped and surface-adsorbed antigens [8]. 
The basis for this immune-potentiating response 
lies in the natural targeting of liposomes to 
antigen-presenting cells (APC), most notably the 
macrophages [9,15]. Cationic liposomes are 
lipid-bilayer vesicle with a positive surface charge 
that has re-emerged as a promising new 
adjuvant technology [10,17]. Although there are 
some evidence that cationic liposome itself can 
improve the immune response against co-
administered vaccine antigens, their main 
functions are to protect the antigens from 
clearance in the body and deliver the antigens to 
professional antigen presenting cells (APC) [11]. 
An immune booster immunace (Vitabiotics, UK) 
contains a comprehensive spectrum of 
antioxidants, vitamins and essential nutrients 
designed to maintain immune resistance and 
long-term cell protection (from free radicals and 
peroxides). Generally, immunace and other 
immune boosters increase the immunity of 
humans and animals by supplying the essential 
nutrients [12,24]. Immune boosters such as 
immunace are given for revitalization and 
improvement of the immune response, especially 
in those with low immunity. Immunace increases 
the amount of antibodies produced, by improving 
and maintaining the immune resistance [12]. In 
this study, the researchers combined two 
immune boosters, DOTAP-based liposome and 
immunace to know the effect of immunace on the 






Cholesterol (Sigma grade, minimum purity 99 %; 
Sigma Aldrich Chemie, St Louis, Missouri, USA), 
DOTAP (Sigma-Aldrich, donation from Prof. 
Godwin Nchinda, Rockefeller University, New 
York, USA), phospholipon 90H (donation from 
Phospholipid GmbH Nattermannallee, Cologne, 
Riedel-de Haen, Seelze Germany), 
methanol(extra pure; ScharlauChemie S.A.), 
chloroform (Sigma-Aldrich GmbH, Germany), live 
La Sota® vaccine (National Veterinary Research 
Institute, Jos, Nigeria), Immunace . 
 
Preparation of the liposome suspension 
 
Lyophilized La Sota® vaccine containing 200 
doses/vial was reconstituted with phosphate-
buffered saline by dissolving a vial in 40 ml 
phosphate buffer solution. Then 196 mg 
phosphatidylcholine, 96.7 mg cholesterol and 50 
mg DOTAP were dissolved in 3 mL 
chloroform/methanol system (2:1) in a round-
bottom flask. The solvent mixture was 
evaporated at room temperature and the flask 
rotated until a smooth, thin, dry film was obtained 
on the wall of the flask [13,26]. Reconstituted 
vaccine (5 ml) was used to hydrate the dry film 
and agitated gently until a milky colloidal 
dispersion was formed. 
  
Transmission electron microscopy 
 
The prepared liposome-encapsulated ND 
vaccines were processed using copper grids to 
adsorb the particles from the suspension, 
staining in 2.5 % uranyl acetate for 30 sec and 
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drying. The specimens were observed under a 
JEM-1010 transmission electron microscope 
(JEOL, Tokyo, Japan) operated at 80 kV at 
x10,500 magnifications [14,27]. 
 
Vesicle size and zeta potential 
 
The z-average vesicle diameter and zeta 
potential of the ND vaccine liposomes in 
phosphate buffer solution (pH7.4) were 
determined by photon correlation spectroscopy 
using a nanosizer 3000 HS (Malvern 
Instruments, Malvern UK). The zeta potential 
was calculated from the mean of three runs. 
Each sample was diluted with bi-distilled water 
and the electrophoretic mobility determined at 25 
oC and a dispersant dielectric constant of 78.5 
and pH 7. The obtained electrophoretic mobility 
values were used to calculate zeta potentials 
using DTS software version 4.1 (Malvern 
Instruments) and applying Henry’s equation 
[15,28]. 
 
UE = {2εZf (K)}/3η  ………………………….  (1) 
 
where Z is the zeta potential, UE the 
electrophoretic mobility, ε the dielectric constant, 
η the viscosity of the medium and f(K) is Henry’s 
function. 
 
Vaccination schedule of the birds 
 
The chicks were raised from 1 day old until 
termination of the experiment. All bird handling 
and experiments were conducted following the 
guidelines stipulated by University of Nigeria 
Research Ethics Committee on animal handling 
and use. Eighty birds were divided into four 
groups of 20 birds each; the unvaccinated group, 
the liposomal ND vaccine group, the liposomal 
ND vaccine + immunace group and the La Sota® 
vaccine group. The different groups were kept in 
separate rooms before vaccination. The 
liposomal ND + immunace group was given 25 
mg/mL of immunace from day old to two weeks. 
At 2 weeks of age, all of the birds were tested for 
the absence of residual haemagglutination 
inhibiting (HI) antibody to Newcastle disease.  
 
At 3 weeks of age, the liposomal ND vaccine 
group and liposomal ND vaccine + immunace 
group were given 0.2 ml/bird (a dose) each of the 
liposomal ND vaccine orally while the La Sota® 
vaccine group were given 0.2 ml/bird (a dose) of 
the reconstituted La Sota® vaccine orally. The 
unvaccinated group served as the control. Two 
weeks after primary vaccination, 10 ml of blood 
was withdrawn from the jugular vein and serum 
samples assessed for antibody to ND virus by 
haemagglutination inhibition (HI) technique 
[16,29]. Booster vaccination was done at 6 
weeks of age. Two weeks after secondary 
vaccination, all birds were bled and serum 
samples assessed for antibody to ND virus. The 
results are presented as the mean with standard 




The results are presented as log2 mean ± 
standard deviation (SD). To determine 
statistically significant difference among the 
means, one-way analysis of variance was 
applied at p < 0.05 using SPPS (version 16.0, 




Transmission electron micrographs 
 
The technique used for the preparation of the 
liposomes was the lipid film hydration technique, 
which formed films on the walls of the flasks and 
on hydration produced a thick, gel-like, milky 
colloidal dispersion. The images of the vesicles, 





The vesical size and zeta potential were 
evaluated using a zeta sizer. The mean size 
distribution and zeta potential were <100 d.nm 
and 24 mV respectively.  
 
Immune response of the birds 
 
All the birds screened prior to administration of 
vaccine were negative for HI antibody. All control 
(unvaccinated) birds had no antibody throughout 
the experiment. The immune response of the 
birds is shown in Table 1. After primary 
vaccination, the liposomal ND vaccine + 
immunace group had the highest mean antibody 
titre (log2) and standard deviation of 6.60 ± 0.0, 
the liposomal ND vaccine group had an antibody 
titre of 5.3 ± 0.56 while the La Sota® vaccine had 
a mean antibody titre of 5.50 ± 0.67 after primary 
immunization. After secondary vaccination the 
chickens further sero-converted, the liposomal 
ND vaccine had the highest mean antibody titre 
(log2) of 9.60 ± 0.95 which was significantly 
higher than the liposomal ND + immunace group 
with a mean antibody titre of 7.00 ± 1.71 and the 
LaSota® vaccine group with (log2) 6.00 ±1.30. 
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Table 1: Immune response of birds after primary and secondary immunization 
 
Treatment group No. of chickens Primary immunization 
(log2) ± SD 
Secondary 
immunization (log2) ± 
SD 
Unvaccinated control 10 0.0A 0.0 
Liposomal ND vaccine 10 5.30+0.56B 9.60+0.95C 
LiposomalND+immunace 
vaccine 
10 6.60+0.0 B 7.00+1.71 B 
La Sota®vaccine 10 5.50+0.67 B 6.00+1.30 B 
* Concentration of the serum antibodies is expressed as HI titre to log base 2. Results presented as the mean 




Liposomes are spherical vesicles composed of 
an aqueous core which is entirely enclosed by a 
membrane composed of phospholipids and 
cholesterol. When these lipids are exposed to an 
aqueous environment, interactions between 
themselves and with water lead to spontaneous 
formation of closed bilayers [17,30]. The fluidity 
or rigidity of the liposomal bilayer, when it is 
made from a single lipid depends on the lipid 
phase transition temperature (Tc) [18,31]. 
Increasing the temperature changes the 
membrane fluidity from a solid-gel phase, where 
the lipid hydrocarbon chains are in an ordered 
state, to a fluid liquid-crystalline phase, a 
disordered state, where molecules have more 
freedom of movement.  
 
Membrane permeability is highest at the phase 
transition temperature, and is lower in the gel 
phase than in the fluid phase. A look at the 
liposomes showed vesicles that were mostly 
spherical in appearance, entrapping the vaccine 
within their core. The vesicles appeared tightly 
packed under the transmission electron 
microscope, indicating that the 
phosphatidylcholine, cholesterol and DOTAP, 
which are amphipathic lipids, thermodynamically 
organized themselves to form stable self-closed 
vesicles. The tight packing of the vesicles may 
also have reduced the binding/insertion of 
proteins, which normally destabilize membranes 
and mark liposomes for removal by phagocytic 
cells. Generally, the more ordered and hence 
tightly packed the membrane of a liposome, the 
less permeable it is [19,32].  
 
Particle size is also one of the determining 
factors for macrophage clearance. Therefore, 
large liposomes are rapidly removed from 
circulation. Photon correlation spectroscopy 
using a zetasizer is a technique that measures 
time-dependent fluctuations in the intensity of 
scattered light and was employed to measure 
size distribution of the particles. If the particle 
size of the liposomes is below 200 d.nm, it would 
escape phagocytosis and the circulation time will 
be prolonged [20,33]. If the circulation time is 
prolonged, there will be more contact time of the 
liposomes with the immune cells, resulting in 
higher immunity. Encapsulation of the ND 
vaccine in the liposomes may also have reduced 
the volume of distribution of the vaccine and 
increased targeting to the immune cells [20,33]. 
 
Knowledge of the zeta potential of the liposomal 
ND vaccine would help to predict its fate in vivo. 
Positively charged liposomes will normally fuse 
with the negatively charged cells. Once 
internalized, the particles are offered to the 
continuous lymphoid tissue so as to protect the 
antigen against degradation on mucosal 
surfaces, and enhance its uptake in mucosa-
associated lymphoid tissue. The vaccines used 
for ND control must be able to protect the 
susceptible poultry against velogenic strains of 
the virus. Antibody titres of 23 are protective, but 
current poultry practices are now designed to 
hyperimmunize chickens to protect them more 
effectively from field/virulent strains of the ND 
virus [21,34]. This could be achieved by 
administering live plus inactivated vaccination to 
boost the antibody titres to as high as 27.  
 
In the study, the objective was to investigate the 
effect of immunace on the established 
immunoadjuvanticity of DOTAP. The primary 
immunization of immunace and DOTAP-based 
ND vaccine produced an antibody titre which was 
higher than DOTAP-based ND vaccine alone. 
After the secondary immunization, the antibody 
titre of DOTAP-based ND vaccine was 
significantly higher than DOTAP-based ND 
vaccine showing that immunace has a short-
acting effect on the immune cells while DOTAP 
has a longer lasting effect on the immune cells. 
Immunoadjuvants are useful in low-biosecurity 
areas with high ND prevalence [22,35]. 
Liposomal ND vaccine, after secondary 
immunization, had a significant effect on the 
immune cells, inducing antibody titres as high as 
29. Association of antigen with liposomes has 
been known to allow the antigen to gain access 
to both the major histocompatibility (MHC) class I 
and class II pathways in antigen presenting cells 
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(APCs). As a result, liposomal antigen can 
stimulate antibody production as well as cellular 




DOTAP-based cationic liposome, based on the 
findings of this study, has demonstrated its ability 
to function as immune adjuvant. Immunace, on 
the other hand, demonstrated a short-lived co-
immunoadjuvanting activity. There was no 
significant immunological relevance for 
combining DOTAP-based ND vaccine and 
Immunace since DOTAP-based cationic 
liposome still gave a significantly higher immune 
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